Clinical trial · Interventional
Genotypification and Predisposing Factors in Human Papilloma Virus Infection
Genotypification and Predisposing Factors in Human Papilloma Virus Infection and Its Association With the Carbohydrate Antigen (CA-125) Tumoral Marker
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objective: Determine the genotypes and risk factors associated with human papilloma virus infection in Mexican women. Methods: It was a cross-sectional study of women attended at the Materno-Perinatal Hospital "Mónica Pretelini" and the Medical Research Center (CICMED), who were asked to complete a risk factor questionnaire and submitted to colposcopy to identify SIL. Cervical swab samples were obtained to perform linear array HPV genotyping test (Roche®, Mannheim, Germany).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Intraepithelial Neoplasia | Intraepithelial Neoplasia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Linear Array HPV Genotyping assay | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- NO_INTERVENTION
- label
- Linear Array HPV Genotyping assay
- description
- Women submitted to colposcopy with a suspicion of squamous intraepithelial lesion were programmed a clinical follow up to cervical swab in order to extract DNA and perform a Linear Array HPV Genotyping assay (Roche®, Mannheim, Germany).
- interventionNames
- Other: Linear Array HPV Genotyping assay
Primary outcomes (1)
- measure
- Multiple HPV infection
- timeFrame
- At the moment of the colposcopy
- description
- While women are revised by colposcopy the Gynecologist will refer them to a cervical swab for DNA extraction in case of suspicious of HPV infection.
Secondary outcomes (1)
- measure
- squamous intraepithelial lesions
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 15 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Sexually active women 18 to 40 years of age who come to consult the dysplasia clinic. * Who are not pregnant * Who have not received pharmacological treatment with antibiotics and / or anti-inflammatory drugs at least one month before the study. * Who agreed to participate in the study and signed the informed consent letter. * Acceptance to fill the questionnaire with relevant data related to HPV risk infection Exclusion Criteria: * Inadequate samples * Questionnaires with incomplete data * Women who decided to leave the study
References
Publications (0)
Data not yet available